Clinical trial readout dates for CRISPR Therapeutics AG, compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is July 2028.
| Phase 1/2 CTX340 Hypertension · NCT07758634 | July 2028 Recruiting |
| Phase 1/2 CTX112 Progressive Multiple Sclerosis (PMS); Neuromyelitis Optica · NCT07804004 | December 2029 Not Yet Recruiting |
| Phase 1/2 CTX112 B-cell Lymphoma; Non-Hodgkin Lymphoma · NCT05643742 | January 2030 Recruiting |
| Phase 1/2 CTX460 Alpha-1 Antitrypsin Deficiency (AATD) · NCT07850076 | June 2030 Recruiting |
| Phase 1/2 CTX112 Warm Autoimmune Hemolytic Anemia (WAIHA); ITP - Immune Thrombocytopenia · NCT07549698 | December 2033 Recruiting |
CRISPR Therapeutics AG reported $2.28B in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-02). Its net loss for that quarter was $111M; at that rate the cash would last about 20 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.
| 8-K Results of Operations — earnings, may carry pipeline updates | 2026-11-02 |